ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02066415
Recruitment Status : Completed
First Posted : February 19, 2014
Results First Posted : June 21, 2018
Last Update Posted : June 21, 2018
Sponsor:
Information provided by (Responsible Party):
Amgen

Brief Summary:
To evaluate the effect of erenumab compared to placebo on the change from baseline in the number of monthly migraine days in adults with chronic migraine.

Condition or disease Intervention/treatment Phase
Treatment for Prevention of Chronic Migraine Biological: Erenumab Drug: Placebo Phase 2

Detailed Description:

This study consisted of the following phases: screening, 4-week baseline phase, 12-week double-blind treatment, and 12-week follow-up. Participants may have elected to participate in the optional pharmacokinetic substudy and the optional, novel patient-reported outcome (PRO) assessment substudy.

Participants who completed the 12-week double-blind treatment phase of Study 20120295 were eligible to enroll in an open-label extension study (Study 20130255; NCT02174861).


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 667 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention
Actual Study Start Date : March 5, 2014
Actual Primary Completion Date : February 24, 2016
Actual Study Completion Date : April 28, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Migraine

Arm Intervention/treatment
Placebo Comparator: Placebo
Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection.
Drug: Placebo
Administered once a month subcutaneously by authorized investigational site study staff.

Experimental: Erenumab 70 mg
Participants received 70 mg erenumab on day 1 and at weeks 4 and 8 by subcutaneous injection.
Biological: Erenumab
Administered once a month subcutaneously by authorized investigational site study staff.
Other Names:
  • AMG 334
  • Aimovig™

Placebo Comparator: Erenumab 140 mg
Participants received 140 mg erenumab on day 1 and at weeks 4 and 8 by subcutaneous injection.
Biological: Erenumab
Administered once a month subcutaneously by authorized investigational site study staff.
Other Names:
  • AMG 334
  • Aimovig™




Primary Outcome Measures :
  1. Change From Baseline in Monthly Migraine Days [ Time Frame: 4-week baseline phase and the last 4 weeks of the 12-week treatment phase ]

    A migraine day was any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined either as a migraine with or without aura.

    The change from baseline in monthly migraine days was calculated as the number of migraine days during the last 4 weeks of the 12-week treatment phase - the number of migraine days during the 4-week baseline phase.



Secondary Outcome Measures :
  1. Percentage of Participants With at Least a 50% Reduction in Monthly Migraine Days From Baseline [ Time Frame: 4-week baseline phase and the last 4 weeks of the 12-week treatment phase ]

    A migraine day was any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined either as a migraine without aura or a migraine with aura. Monthly migraine days were calculated as the number of migraine days in the 4-week baseline phase and during the last 4 weeks of treatment.

    At least a 50% reduction from baseline in monthly migraine days was determined if the change in monthly migraine days from the 4-week baseline phase to the last 4 weeks of the 12-week treatment phase * 100 / baseline monthly migraine days was less than or equal to -50%.


  2. Change From Baseline in Monthly Acute Migraine-specific Medication Treatment Days [ Time Frame: 4-week baseline phase and the last 4 weeks of the 12-week treatment phase ]
    Monthly acute migraine-specific medication treatment days is the number of days on which migraine specific medications were used between monthly doses of study drug. Migraine-specific medications includes two categories of medications: triptan-based migraine medications and ergotamine-based migraine medications.

  3. Change From Baseline in Cumulative Monthly Headache Hours [ Time Frame: 4-week baseline phase and the last 4 weeks of the 12-week treatment phase ]

    The cumulative duration of any qualified headache between monthly doses of study drug regardless of acute treatment use.

    A qualified headache was defined as follows:

    • a qualified migraine headache (including an aura-only event that is treated with acute migraine-specific medication), or
    • a qualified non-migraine headache, which is a headache that lasted continuously for ≥ 4 hours and was not a qualified migraine headache, or
    • a headache of any duration for which acute headache treatment was administered.

  4. Number of Participants With Adverse Events [ Time Frame: From the first dose of study drug up to 16 weeks after the last dose (24 weeks) ]

    Adverse events (AEs) were graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4, where:

    Grade 1 = Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2 = Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL); Grade 3 = Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL; Grade 4 = Life-threatening consequences; urgent intervention indicated Grade 5 = Death related to AE.


  5. Number of Participants Who Developed Antibodies to Erenumab [ Time Frame: Baseline and weeks 2, 4, 8, 12 and 24 ]

    Blood samples were first tested in an electrochemiluminescence (ECL)-based bridging immunoassay to detect anti-drug antibodies (ADA) against erenumab. Samples confirmed to be positive for binding antibodies were subsequently tested in a cell-based bioassay to determine neutralizing activity against erenumab (Neutralizing Antibody Assay).

    Developing antibody incidence indicates participants with a negative or no result at baseline and a positive result at any time post-baseline.

    If a sample was positive for binding antibodies and demonstrated neutralizing activity at the same time point, the sample was defined as positive for neutralizing antibodies.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • History of at least 5 attacks of migraine without aura and/or migraine with visual sensory, speech and/or language, retinal or brainstem aura.
  • History of ≥ 15 headache days per month of which ≥ 8 headache days were assessed by the subject as migraine day.
  • ≥ 4 distinct headache episodes, each lasting ≥ 4 hours OR if shorter, associated with use of a triptan or ergot-derivative on the same calendar day based on the eDiary calculations.
  • Demonstrated at least 80% compliance with the eDiary.

Exclusion Criteria:

  • History of cluster headache or hemiplegic migraine headache
  • Unable to differentiate migraine from other headaches
  • Failed > 3 medication categories due to lack of efficacy for prophylactic treatment of migraine .
  • Received botulinum toxinin head or neck region within 4 months prior to screening.
  • Used a prohibited migraine prophylactic medication, device or procedure within 2 months prior to the start of the baseline phase

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02066415


  Show 74 Study Locations
Sponsors and Collaborators
Amgen
Investigators
Study Director: MD Amgen

Additional Information:
Publications:
Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT02066415     History of Changes
Other Study ID Numbers: 20120295
2013-001707-36 ( EudraCT Number )
First Posted: February 19, 2014    Key Record Dates
Results First Posted: June 21, 2018
Last Update Posted: June 21, 2018
Last Verified: January 2018

Keywords provided by Amgen:
Chronic Migraine

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases